Multiple endocrine neoplasia type 2 screening: Difference between revisions
Line 26: | Line 26: | ||
}}</ref> | }}</ref> | ||
|} | |} | ||
* The [[DNA]]-based testing of the c-RET gene can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-RET germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of | * The [[DNA]]-based testing of the c-''RET'' gene can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-''RET'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. This test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]]. Moreover, the aggressiveness of [[medullary thyroid cancer]] correlates with the specific c-''RET'' codon mutation and this strong genotype-phenotype correlation that ulteriorly contributes to the clinical management of patients. Specific c-''RET'' mutations, in fact, are associated to peculiar clinical [[phenotype]]s and thus to different course and [[prognosis]] of the [[disease]]. | ||
* [[Screening]] of the [[pregnant]] woman with increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the ''RET'' gene of the offspring. | * [[Screening]] of the [[pregnant]] woman with increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the ''RET'' gene of the offspring. | ||
Revision as of 00:53, 29 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- Screening for multiple endocrine neoplasia type 2 include the following.
References
|